{"entity":{"id":"nct07533123","kind":"trial","name":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care","aka":[],"tldr":"A phase 3 trial testing JSKN016 in triple-negative breast cancer, now recruiting.","summary":"A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care is a phase 3 interventional study registered as NCT07533123, led by Jiangsu Alphamab Biopharmaceuticals, and recruiting on the registry. Official title: A Randomised, Controlled, Open-Label Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Triple-Negative Breast Cancer Who Have Failed at Least Two Lines of Prior Systemic Therapy. Planned enrolment is 364 participants (estimated). The study started in 2026-03-17 and primary completion is expected in 2029-03-17. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07533123","url":"https://clinicaltrials.gov/study/NCT07533123"}],"tags":["ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-metastatic"],"sections":[],"technologies":[],"targets":[],"drugs":["jskn016"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07533123","phase":"3","setting":"A Randomized, Controlled, Open-Label Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Triple-Negative Breast Cancer Who Have Failed at Least Two Lines of Prior Systemic Therapy","sponsor":"Jiangsu Alphamab Biopharmaceuticals","started":"2026-03-17","startedType":"estimated","enrolled":364,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07533123/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"jskn016","kind":"drug","name":"JSKN016","route":"/drugs/jskn016/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}